Merck’s impressive Q3 earnings, marked by strong vaccine sales and cost-cutting measures, are likely to have a positive short-term impact on its stock price. The successful uptake of GARDASIL and JANUVIA, along with cost efficiencies and Wise initiatives, position the company well for the future. However, the stock’s recent performance and theciosa’s uncertainties mean the impact may be neutralised in the short term. ([1])